Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PH-762
- Development stage
- Phase 1
- Lead developer
- Phio Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Subcutaneous
01
Overview
PH-762 is a self-delivering, chemically modified small interfering RNA (siRNA) therapeutic designed to silence the expression of programmed cell death protein 1 (PD-1, also known as PDCD1) in T cells. By inhibiting PD-1, an immune checkpoint that downregulates T-cell activation and proliferation, PH-762 restores immune function and enhances cytotoxic T lymphocyte-mediated anti-tumor responses. The drug is based on Phio Pharmaceuticals' INTASYL platform and is administered intratumorally or subcutaneously. It is under clinical development primarily for solid tumors including melanoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, ovarian cancer, colon cancer, hepatocellular carcinoma, and metastatic melanoma[2][3][4][5][6][8].
- Brand names
- RXI-762RXI762RXI 762
- Other names
- anti-PD-1 siRNA PH-762anti-PD1 siRNA PH-762anti-PD 1 siRNA PH-762
02
Targets
GRAMD4 (GRAM domain-containing protein 4)Programmed cell death 1 (PDCD1) mRNA/pre-mRNA
Beyond the preview
Go deeper on PH-762.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PH-762.